Company intelligence / Profile preview

NovaScan

Chicago, Illinois, United States

Ownership: Private
Development stage: Clinical

Overview

NovaScan’s MarginScan™ and Canary devices have demonstrated high sensitivity and specificity for real-time, point-of-care detection of various cancers. Over 750 patients have been enrolled in multiple clinical trials across several tumor types, with results presented at major dermatology meetings. The MarginScan™ device is being commercialized for intraoperative use during Mohs surgery for skin cancers, while the Canary device is under trial for pancreatic applications

Therapeutic areas: Oncology
Modalities: DeviceDiagnostic platform (bioimpedance-based)
Industry: Physiological Monitoring

Partnerships

Epredia (distribution agreement intent announced for U.S. distribution of MarginScanTM device)

Beyond the preview

Go deeper on NovaScan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovaScan.

Explore the full profile